Get the Stockscreener App
143.21
3.75%
5.17
After Hours:
143.21
Neurocrine Biosciences Inc stock is traded at $143.21, with a volume of 1.33M.
It is up +3.75% in the last 24 hours and up +2.02% over the past month.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
See More
Previous Close:
$138.04
Open:
$138.04
24h Volume:
1.33M
Relative Volume:
1.45
Market Cap:
$14.20B
Revenue:
$2.41B
Net Income/Loss:
$305.80M
P/E Ratio:
48.55
EPS:
2.95
Net Cash Flow:
$492.20M
1W Performance:
-0.55%
1M Performance:
+2.02%
6M Performance:
+32.98%
1Y Performance:
+19.07%
1-Day Range:
$137.06
$143.47
1-Week Range:
$133.61
$149.98
52-Week Range:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
143.21 | 13.76B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
144.09 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.44 | 41.80B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.27 | 40.88B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.48 | 22.98B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
445.43 | 19.53B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
How big funds are accumulating Neurocrine Biosciences Inc. (NB3) stockTrade Volume Summary & Precise Buy Zone Identification - newser.com
Applying sector rotation models to Neurocrine Biosciences Inc.Portfolio Gains Report & Fast Entry Momentum Trade Alerts - newser.com
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
TransThera Sciences Sells NLRP3 Inhibitor License to Neurocrine Bioscience - MarketScreener
TransThera Sciences Partners with Neurocrine for NLRP3 Inhibitors Development - TipRanks
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockQuarterly Trade Report & Daily Stock Trend Reports - newser.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.2025 Market Overview & Daily Oversold Bounce Ideas - newser.com
How risky is Neurocrine Biosciences Inc. stock nowEarnings Miss & Real-Time Volume Trigger Notifications - newser.com
1,945 Shares in Neurocrine Biosciences, Inc. $NBIX Purchased by Daymark Wealth Partners LLC - MarketBeat
What analysts say about Neurocrine Biosciences Inc stockMarket Timing Techniques & Explosive Trading Portfolio - earlytimes.in
Is It Time to Lock in Profits on Winsol Engineers Limited StockPrice Volatility Patterns & Exceptional Trading Strategies - earlytimes.in
What data driven models say about Neurocrine Biosciences Inc.’s futureJuly 2025 Sentiment & AI Based Buy/Sell Signal Reports - newser.com
Cantor Fitzgerald Brokers Raise Earnings Estimates for NBIX - MarketBeat
Brighton Jones LLC Invests $351,000 in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Short interest data insights for Neurocrine Biosciences Inc.Trade Analysis Report & Long-Term Safe Investment Plans - newser.com
Neurocrine Biosciences (NASDAQ:NBIX) Given Buy Rating at Truist Financial - MarketBeat
Will Neurocrine Biosciences Inc. (NB3) stock return to pre crash levels2025 Price Targets & AI Optimized Trading Strategy Guides - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyTake Profit & Real-Time Chart Pattern Alerts - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.2025 Market Sentiment & Verified Technical Trade Signals - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikesMarket Growth Review & Consistent Profit Focused Trading Strategies - newser.com
Jennison Associates LLC Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
What analysts say about Neurocrine Biosciences Inc NB3 stockHealthcare Stock Analysis & Minimal Capital Trading Tips - earlytimes.in
Is The Indian Link Chain Manufactures Limited a Growth Buy or Value Trap This YearFundamental Strength Indicators & Free Daily Stock Hotspot Analysis - earlytimes.in
What moving averages say about Neurocrine Biosciences Inc.July 2025 News Drivers & Consistent Growth Stock Picks - newser.com
INGREZZA and CRENESSITY Sales Beat Might Change the Case for Investing in Neurocrine Biosciences (NBIX) - simplywall.st
Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win - BioPharma Dive
Neurocrine Biosciences (NASDAQ:NBIX) Given New $164.00 Price Target at Canaccord Genuity Group - MarketBeat
Focus Partners Advisor Solutions LLC Takes $660,000 Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Citigroup Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap DownWhat's Next? - MarketBeat
Piper Sandler Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat
Needham & Company LLC Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2025 Earnings Call Transcript - Insider Monkey
How to build a dashboard for Neurocrine Biosciences Inc. stockPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Neurocrine Biosciences (NBIX): Net Margin Miss Challenges Bullish Earnings Growth Narratives - Yahoo Finance
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 8,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Oppenheimer Asset Management Inc. - MarketBeat
Can Neurocrine Biosciences Inc. stock sustain revenue growthJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - newser.com
Piper Sandler Maintains Neurocrine Biosciences (NBIX) Overweight Recommendation - Nasdaq
Is Now the Right Time to Reassess Neurocrine Biosciences After Expansion News and Valuation Gaps? - simplywall.st
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):